// App-Quantinova.ai

: A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Researchers

Presenter

  • Hironori Arai

Principal Investigators

  • Yoshikazu Utsu

  • Shinichi Masuda

  • Nobuyuki Aotsuka

  • Tomoaki Ueda

  • Kentaro Fukushima

  • Daisuke Ikeda

  • Naoko Hosono

  • Takahiro Yamauchi

  • Goichi Yoshimoto

  • Hiroto Horiguchi

  • Satoshi Iyama

  • Junya Kanda

  • Seiichiro Katagiri

  • Akihiko Gotoh

  • Daisuke Koyama

  • Takayuki Ikezoe

  • Takeshi Kondo

  • Yukinori Nakamura

  • Fumiya Ogasawara

  • Suguru Fukuhara

  • Koji Izutsu

  • Nobuhiko Yamauchi

  • Junichiro Yuda

  • Yosuke Minami

Medical Centers

  • Department of Hematology, Fukushima Medical University School of Medicine, Fukushima, Japan

  • Third Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan

  • Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

  • Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan

  • National Cancer Center Hospital East, Kashiwa, Japan

  • Department of Hematology, Kochi University Hospital, Nankoku, Japan

  • Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan

  • Department of Hematology, Tokyo Medical University, Tokyo, Japan

  • Division of Hematology/Oncology, Kameda Medical Center, Kamogawashi, Japan

  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita-city,Osaka, Japan

  • Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan

  • Aiiku Hospital, Sapporo, Japan

  • Department of Hematology, Saga Prefectural Medical Center Koseikan, Saga, JPN

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Alpha-tubulin N-acetyltransferase 1

  • Nucleophosmin 1

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • E3 ubiquitin-protein ligase CBL

  • Enhancer of zeste homolog 2

  • KRAS proto-oncogene, GTPase

  • ETV6-RUNX1

  • GTPase Nras

  • Fms related tyrosine kinase 3

  • Isocitrate dehydrogenase 1

  • Isocitrate dehydrogenase 2

  • Tumor protein p53

  • Neurofibromatosis type 1

Drug/Treatment

  • Fuldazin

  • HM01

  • HM02

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • Multicenteric

  • KRAS

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved